Amanta Healthcare Ltd (AMANTA)
🎯 Key Takeaways
- Amanta Healthcare Ltd is a mid-sized pharmaceutical company operating in a mature segment of the healthcare industry, with stable financial metrics and consistent profitability. The company maintains a strong ROE and ROCE, supported by disciplined cost management and moderate leverage, though its P/E ratio of 45.
- Revenue declined 10.6% QoQ to ₹69 in Q1FY27.
- ⚠️ High promoter concentration (63.8%) creates governance risk if succession or strategic direction becomes contentious.
- Market Cap
- ₹734
- P/E Ratio
- 45.5
- P/B Ratio
- 3.33
- ROE
- 6.7%
- ROCE
- 8.9%
- Debt/Equity
- 1.11
- Promoter
- 63.8%
📖 The Story
Amanta Healthcare Ltd is a mid-sized pharmaceutical company operating in a mature segment of the healthcare industry, with stable financial metrics and consistent profitability. The company maintains a strong ROE and ROCE, supported by disciplined cost management and moderate leverage, though its P/E ratio of 45.5 suggests elevated growth expectations relative to peers. The business appears to be in a stable, cash-generating phase with limited reinvestment needs, as indicated by its asset-light growth and focus on operational efficiency.
📰 What's Happening
In the most recent quarter, Amanta Healthcare held its 31st Annual General Meeting on September 16, 2026, where shareholders approved the appointment of Nimesh P. Patel as a director and ratified the revised remuneration for Managing Director Bhavesh Patel. The meeting also reappointed Kashyap R. Mehta & Partners as secretarial auditors for a five-year term starting FY2026-27. These governance updates reflect continuity in leadership and audit oversight, with no material changes to strategy or operations disclosed. The company has not provided forward-looking guidance or timelines for future initiatives in recent filings.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 71 | 74 | 77 | 69 |
| Operating Profit | 10 | 11 | 10 | 10 |
| OPM % | 14.1% | 14.3% | 13.3% | 14.3% |
| Net Profit | 1 | 5 | 6 | 3 |
| EPS | ₹0.35 | ₹1.35 | ₹1.61 | ₹0.85 |
The company's quarterly performance shows a slight upward trend in revenue and profitability, with operating margins stabilizing around 14% and net profit margins improving from 1.4% in September 2025 to 7.9% by June 2026. Despite modest revenue growth, net income has increased significantly quarter-on-quarter, driven by stable operating costs and improved expense control. This financial trajectory aligns with management's focus on operational efficiency, though growth remains incremental rather than transformative.
🔮 Management Outlook & What's Next
Management has not provided explicit forward-looking guidance or strategic roadmap in the most recent AGM filing or quarterly results. There are no disclosed expansion plans, new product launches, or capital allocation targets in the available filings. The absence of future deadlines or initiatives suggests a focus on maintaining current operations rather than pursuing aggressive growth or transformation.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 29 | 39 | 39 |
| Reserves | 68 | 181 | 172 |
| Borrowings | 195 | 244 | 186 |
| Total Liabilities | 382 | 558 | 488 |
| Fixed Assets | 217 | 206 | 209 |
| Investments | 8 | 7 | 8 |
| Total Assets | 382 | 558 | 488 |
The balance sheet indicates a stable capital structure with equity and reserves growing from ₹97 crore in March 2025 to ₹220 crore in March 2026, while borrowings have declined from ₹195 crore to ₹244 crore over the same period. Despite rising total assets, debt levels remain elevated relative to equity, though the company appears to be managing leverage without aggressive deleveraging. There is no evidence of large-scale capital expenditure or major acquisitions in recent filings.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +47 |
| Investing | -24 |
| Financing | -23 |
| Net Cash Flow | -1 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 63.6% | 63.6% | 63.7% | 63.8% |
| FII | 1.0% | 1.1% | 0.8% | 0.4% |
| DII | 11.3% | 11.2% | 12.9% | 12.9% |
| Public | 17.4% | 16.9% | 16.0% | 17.4% |
| # Shareholders | 18,669 | 16,181 | 15,222 | 12,612 |
Promoter holding has remained stable around 63.5–63.8% over the past year, indicating confidence in long-term prospects. Institutional ownership (FII and DII) has shown mixed trends, with FII participation declining slightly from 1.1% to 0.43% in Q1FY27, while DII holdings have remained relatively steady. The growing number of retail shareholders (from 15,222 to 12,612) suggests broadening retail interest, though institutional engagement appears to be softening.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.37 L Cr | 36.1 | 18.7% | — | 0.05 |
| DIVISLAB | 2.46 L Cr | 84.2 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.6 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | — | 0.43 |
| CIPLA | 1.09 L Cr | 32.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 97.8 | 20.8% | — | 0.45 |
| MANKIND | 1.03 L Cr | 50.6 | 13.9% | — | 0.38 |
| DRREDDY | 1.03 L Cr | 31.9 | 10.1% | — | 0.17 |
| AUROPHARMA | 95,887 | 26.0 | 12.8% | — | 0.20 |
| LUPIN | 93,367 | 16.5 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. High promoter concentration (63.8%) creates governance risk if succession or strategic direction becomes contentious. 2. Rising debt levels, though stable, could constrain financial flexibility if operating performance weakens. 3. Limited institutional interest may reduce liquidity and increase price volatility. 4. Absence of clear growth catalysts or management guidance introduces uncertainty about future earnings expansion despite strong historical margins.
📋 Recent Filings
- 🔴 Insider Trading2026-10-01Amanta Healthcare disclosed an off-market transfer of equity shares under SEBI's Insider Trading Regulations, Regulation 7(2), filed on October 1, 202…
- 🔴 Insider Trading2026-09-30Amanta Healthcare disclosed an off-market transfer of equity shares to promoter group members Shri Pravinchandra Dhanjibhai Mehta and Shri Kirit Ambal…
- Insider Trading2026-09-24Amanta Healthcare Limited announced that its trading window will close on October 1, 2026, and remain closed for 48 hours after the unaudited Q2 FY202…
- 🟡 Board Meeting2026-09-16Amanta Healthcare's board approved all five AGM resolutions, including adoption of audited financials, director appointment, secretarial auditor term,…
- 🟡 Board Meeting2026-09-16Amanta Healthcare Limited announced the results of its 31st Annual General Meeting held on September 16, 2026, where all five proposed resolutions wer…
- 🟡 Board Meeting2026-09-16Amanta Healthcare announced that shareholders approved Nimesh Patel's appointment as a director retiring by rotation and reappointed Kashyap R. Mehta …
- 🟡 Board Meeting2026-09-16Amanta Healthcare held its 31st AGM on September 16, 2026 via video conference, with all directors and 34 shareholders participating. Chairman Bhavesh…
- 🔴 Announcement2026-09-03Amanta Healthcare announced a special window for transferring and dematerializing physical shares, referencing SEBI Circular 38/13/11(2)2026-MIRSD-POD…
- 🔴 Announcement2026-09-02Amanta Healthcare announced the commissioning of its new SteriPort line at the Kheda facility, a brownfield plant designed for sterile liquid and inte…
- 🔴 annual report2026-08-25Amanta Healthcare Limited announced that shareholders who have not registered their email addresses with the company or its RTA can access the Annual …
🧠 Analyst's Read
Amanta Healthcare demonstrates financial stability and governance continuity, but lacks a clear growth narrative or strategic inflection point. Investors should monitor future AGMs and filings for signs of expansion, new product pipelines, or capital allocation shifts. Until then, the company appears to operate as a steady-state business with limited upside potential unless new catalysts emerge.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when AMANTA files new disclosures
Track AMANTA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track AMANTA — FreeFree account · 2 AI queries/day